PHVSPharvaris N.V.

Healthcare
$31.14+23% 1Y

The financials

Pharvaris N.V. by the numbers

Pharvaris N.V. income statement, H2 2025 against the same quarter a year earlier
Income statementH2 2025Q2 2024Change
Operating income−€82M−€30Mn/a
Net income−€84M−€30Mn/a
Diluted EPS−€1.29−€0.55n/a

Biotechnology

Ranks #114 of 196 by RyuScore

Compare peers
NRIX+0.68%
Nurix Therapeutics, Inc.
MLYS+4.4%
Mineralys Therapeutics, Inc.
BHVN+1.3%
Biohaven Ltd.
SLBT-1.3%
SL Science Holding Limited
MBX+0.16%
MBX Biosciences, Inc.
MRVI+3.7%
Maravai LifeSciences Holdings, Inc.